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Lignans and proanthocyanidins are plant polyphenols that have shown protective properties against colorectal neoplasms in
some human studies. Using logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) to
prospectively evaluate the association between lignan and proanthocyanidin intake, estimated from databases linked to a
food frequency questionnaire, and adenoma recurrence in 1,859 participants of the Polyp Prevention Trial. Overall, individual
or total lignans or proanthocyanidins were not associated with colorectal adenoma recurrence. However, in sex-specific
analyses, total lignan intake was positively associated with any adenoma recurrence in women (highest vs. lowest lignan
intake quartile OR 5 2.07, 95% CI: 1.22–3.52, p trend 5 0.004) but not in men (p interaction 5 0.04). To conclude, dietary
lignan and proanthocyanidin consumption were not generally related to colorectal adenoma recurrence; however, high lignan
intake may increase the risk of adenoma recurrence in women.
Polyphenols have generated interest as components of fruits
and vegetables that show cancer protective properties.
1,2 On
the basis of their chemical structure, polyphenols are divided
into subclasses, the most pertinent being tannins (proantho-
cyanidins, hydrolysable tannins), lignans, stilbenes, phenolic
acids and ﬂavonoids.
3 We previously showed that the ﬂavonoid
subgroups ﬂavonols and isoﬂavonoids and the ﬂavan-3-ol epi-
gallocatechin-3-gallate (EGCG) decrease the risk of advanced
adenoma recurrence in the Polyp Prevention Trial (PPT).
4,5
Lignans are diphenolic compounds present in the ﬁbrous
portion of plants, which are (partially or fully) converted by
microbial gut ﬂora to enterolactone and enterodiol.
6 The
richest dietary sources of lignans are ﬂax or linseed and ses-
ame seed (3.5 g/kg).
7 Beverages (wine, tea, coffee and orange
juice), cereals, bread, legumes, fruits (strawberries, peaches
and oranges) and vegetables (broccoli, squash and cabbage)
are, despite having 100–1,000-fold lower lignan contents than
ﬂax or sesame seed, the major dietary sources of lignans.
8–11
The antioxidative, anti-inﬂammatory and phytoestrogenic
properties of lignans and their metabolites, as well as their
ability to inhibit proliferation, invasion and angiogenesis and
to promote apoptosis
12–17 suggest a plausible role for them in
chemoprevention of colorectal carcinogenesis. Results from
human studies are mixed with lignan consumption being
associated with increased risk of colorectal cancer in a Cana-
dian case-control study but a decreased risk in an English
nested case-control study.
11,18 The association between lignan
intake and colorectal cancer may differ between men and
women, as sex modiﬁed the association between enterolac-
tone concentrations and colorectal cancer in both a Danish
and an English nested case-control study.
18,19 Dietary ﬁber
and fat may modify the association between lignan intake
and colorectal cancer by altering the intestinal microﬂora
and, thus, the conversion of plant lignans to the more bioac-
tive enterolactone and enterodiol
20; as such, lignan intake
and enterolactone concentration produced opposing results
in relation to colorectal cancer in the English nested case-
control study.
18 Furthermore, dietary lipids may alter the
effect of lignans on the metabolism of steroid hormones,
6,21
which are involved in the etiology of colorectal tumorigene-
sis, as lignans and lipids are both involved in steroid hor-
mone synthesis and metabolism.
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IJCProanthocyanidins (e.g., condensed tannins) are polymers
of elementary ﬂavan-3-ol units and are common constituents
of U.S. diets.
22–24 The main dietary sources of proanthocyani-
dins are fruits (grapes, apples and plums), legumes (dry beans),
beverages (red wine, tea, cocoa and fruit juices) and choco-
late.
23,25,26 Their antioxidant, anti-mutagenic, anti-inﬂamma-
tory and antimicrobial activity, along with their ability to
chelate metal ions, proteins and toxins, promote apoptosis and
inhibit proliferation supports their role in chemoprevention of
colorectal cancer in animal and in vitro studies.
22,27,28 The
results from human studies, however, are less convincing: a
Scottish and an Italian case-control study reported an inverse
association between proanthocyanidin intake and colorectal
cancer risk
29,30; whereas another Scottish case-control study, as
well as the prospective Iowa Women’s Health Study reported
no association with colorectal cancer.
31,32
The objective of our study was to prospectively evaluate
whether consumption of lignans and proanthocyandins, over-
all or stratiﬁed by gender and key dietary factors, was associ-
ated with colorectal adenoma recurrence in the PPT. To our
knowledge, this is the ﬁrst study to prospectively evaluate
this relationship.
Material and methods
Study design and population
The PPT was a 4-year randomized, multi-center, nutritional
intervention trial to evaluate whether an intervention
designed to encourage consumption of a high-ﬁbre, high-fruit
and high-vegetable, and low-fat diet would decrease the risk
of adenoma recurrence. Details of the study have been previ-
ously described.
33–35 To be eligible for the study, participants
had at least one histologically conﬁrmed colorectal adenoma
identiﬁed by complete colonoscopy in the 6 months before
study entry. Our study included 1,859 participants of the
control (n ¼ 930) and the intervention arm (n ¼ 929) that
had a colonoscopy at baseline (T0) and at the end of the
four year trial (T4), as well as dietary data for any of the ﬁrst
3 years of the study (T1, T2 or T3). The institutional review
boards of the National Cancer Institute and each participat-
ing center approved the study and all participants provided
written informed consent.
Adenoma assessment
At baseline (T0), 1 year later (T1), and 4 years after baseline
(T4), participants had a full colonoscopy. Participants who
missed the T1 colonscopy (8.2%) had a full colonscopy by
the end of year T2. The ﬁrst two colonoscopies were clearing
colonoscopies used to remove any existing adenomas,
whereas the T4 colonoscopy and any unscheduled colono-
scopy after Year 2 (1.31 colonoscopies per participant after
year 2) was used to determine adenoma recurrence. All colo-
rectal lesions were evaluated for histologic features, size and
degree of atypia by two independent pathologists. Adenomas
detected after 2 years were considered as recurrent adenomas.
Adenomas that were at least 1 cm in size, had at least 25%
villous components, or showed high grade dysplasia were
classiﬁed as advanced adenomas. High risk adenoma recur-
rence was deﬁned as having at least three pathologically con-
ﬁrmed adenomas of any size or an advanced adenoma at T4.
Lignan and proanthocyanidin data
At T0 and at each of the annual follow-up visits, participants
completed a self-administered modiﬁed Block-National Cancer
Institute Food Frequency Questionnaire (FFQ), which asked
about the frequency of intake and portion size of 119 food
and beverage items during the past year.
34,35 Some FFQ food
items were a single fruit or vegetable, such as apples, whereas
others were grouped food items, such as ‘‘other fruits,’’ which
included grapes, plums and pineapples. Trained, certiﬁed
nutritionists reviewed all FFQs with participants.
36 Compared
with 24-hr dietary recalls and four-day food record data, the
FFQ slightly overestimated fat and underestimated ﬁber, fruit
and vegetable intake and had acceptable correlations for fat
(r ¼ 0.63), ﬁbre (r ¼ 0.63), fruit and vegetable (r ¼ 0.72), dry
bean (r ¼ 0.76) and other macro- and micro-nutrients. With
respect to foods with available lignan data, the FFQ asked
three questions on legumes, one on nuts, 17 on vegetables
(including soups), 11 on fruits, nine on breads/cereals, 13 on
beverages and 11 on processed food consumption. The FFQ
did not speciﬁcally ask questions on intakes of ﬂaxseed, linseed
or sesame seed, which are enriched in lignans, because these
were rarely consumed in the U.S. when the PPT was con-
ducted. Lignan intake was estimated for 58 of 65 food and
beverage items using a Canadian phytoestrogen database and
was calculated as the sum of lariciresinol, matairesinol, pinore-
sinol and secoisolariciresinol.
8 Three other phytoestrogen data-
bases
10,37,38 were used for seven food items (brown or wild
rice, brussel sprouts, chocolate candy, other vegetables, peas,
popcorn and spaghetti) not included in the Canadian database.
The four databases were similar in lignan concentrations of
common foods and beverages. With respect to foods with
available proanthocyanidin data, the FFQ asked 11 questions
on fruits, 21 on vegetables (including soups), 12 on beverages
(including beer, fruit juices, tea and wine) and one on choco-
late consumption. Proanthocyanidin intake was estimated
from the 2004 U.S. Department of Agriculture (USDA)
comprehensive proanthocyanidin database
26 that reviewed,
evaluated and summarized the existing proanthocyanidin data-
bases and calculated the sum of monomers, dimers, trimers,
4–6 mers, 7–10 mers and polymers (>10 ﬂavan-3-ol units).
The FFQ was not speciﬁcally validated for lignan and pro-
anthocyanidin intake using 24-hr dietary recalls and four-day
food record data. Lignan and proanthocyanidin intake from
dietary supplements was not included because the intake of
supplements containing signiﬁcant amounts of lignans and
proanthocyanidins was low in the PPT.
Lifestyle data
Besides the FFQ completed at T0 and the annual follow-up
visits, participants also completed an interviewer-administered
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Int. J. Cancer: 130, 1649–1659 (2012) 2011 UICCquestionnaire about demographics (including age, gender and
education level), physical activity, smoking (including inten-
sity and duration of smoking), family history of cancer
(including number of ﬁrst-degree relatives with cancer), clini-
cal visits, and medication and supplement use (including
name, dosage and frequency of use). Regular non-steroidal
anti-inﬂammatory drug (NSAID) use was deﬁned as taking
aspirin or non-aspirin NSAIDs such as ibuprofen, naproxen,
indomethacin or piroxicam at least once per month. Hor-
mone replacement therapy among women was deﬁned as tak-
ing either unopposed estrogens or estrogen/progestin combi-
nations. Physical activity was deﬁned as self-reported time
typically spent for any type of moderate or vigorous physical
activity, including both occupational and non-occupational
activities.
Statistical analyses
Statistical analyses were performed using SAS, version 9.1
(SAS, Cary, NC) software. Baseline participant characteristics
and dietary intakes of lignans, proanthocyanidins and pri-
mary dietary sources of lignans and proanthocyanidins [at
T0, and during the ﬁrst 3 years of the trial (mean of T1, T2
or T3)] were evaluated by adenoma recurrence at T4 (any or
high risk adenoma recurrence vs. no recurrence) using Wil-
coxon rank sum test for continuous variables and Fisher’s
exact test for categorical variables. Dietary data from T4 was
not used because it was collected after colonoscopy (used for
assessing adenoma recurrence) in some participants. Spear-
man’s and Pearson’s correlation coefﬁcients between lignans,
proanthocyanidins and primary dietary sources of lignans
and proanthocyanidins were calculated.
The association between dietary intakes of lignans and
proanthocyanidins [T0 (not shown in Tables) and mean of
T1, T2 and T3 (shown in the Tables)] and colorectal ade-
noma recurrence was evaluated by odds ratios (ORs) and
95% conﬁdence intervals (95% CI) using multivariate logistic
regression. A linear trend test was performed using the ln-
transformed median value of each dietary intake quantile as
a continuous variable in a logistic regression model. Partici-
pants characteristics, listed in Table 1, were evaluated as
potential confounders by adding them in a stepwise manner
to the model. Potential confounders remained in the model if
they changed the association by >10%, had a v
2 p value  
0.20, and were associated with both adenoma recurrence and
lignan or proanthocyanidin intake. Saturated fat intake was a
confounder for the association between proanthocyanidin
consumption and adenoma recurrence but not for the associ-
ation between lignan consumption and adenoma recurrence.
Two multivariate logistic regression models are shown: (a)
crude analysis [age quartiles, sex and energy intake (continu-
ous) during the ﬁrst three trial years] and (b) multivariate
analysis [age quartiles, sex, BMI, NSAID use at baseline,
energy intake (continuous) and saturated fat intake (quartiles,
only for proanthocyanidins) during the ﬁrst three trial years].
To evaluate the statistical power to see a biologically
meaningful effect of lignan and proanthocyanidin consump-
tion on any or advanced adenoma recurrence, we used
Monte Carlo simulation of 2,000 computer-generated datasets
with the sample size of the trial (464 individuals in each of
the four quartiles) and a true relationship described by an
OR of 0.88, 0.79 and 0.70 in the second, third and fourth
quartiles (relative to the ﬁrst quartile) and computed the pro-
portion that were statistically signiﬁcant at the 0.05 signiﬁ-
cance level (with a two-sided trend test). Age, gender, BMI,
regular NSAID use and dietary fat intake [the available varia-
bles were total fat, total saturated fat, oleic acid, linoleic acid
and saturation index (proportion of saturated fatty acids on
total fatty acids)] were evaluated for effect modiﬁcation. For
continuous variables, the median values were used as cutoffs
(  median and > median). The interaction p-value for the
stratiﬁed data was calculated from the interaction term
between the ln-transformed median value of each dietary
intake quartile as a continuous variable and the categorical
variable evaluated for effect modiﬁcation. All p values were
considered statistically signiﬁcant at either p   0.05, or after
adjusting for multiple comparisons using the Bonferroni cor-
rection at p   0.008.
Results
At the end of the 4-year trial, 40% of participants had at least
one recurrent adenoma, 12% had high risk adenoma and 7%
had an advanced adenoma recurrence (Table 1). Adenoma
recurrence was more common in men and older individuals,
and less common in women who used hormone therapy. In
addition, advanced adenoma recurrence was more common
in individuals who did not regularly use NSAIDs (Table 1).
Intake of lignans and proanthocyanidins was log-normally
distributed and, therefore, is shown as median and quartile
intakes (Table 1). At baseline, lignan and proanthocyanidin
consumption as a percentage of total energy intake was
higher in females than males (both p < 0.0001).
Compared to baseline, total daily lignan consumption
increased on average from 135 to 167 lg during the ﬁrst 3
years of the trial (p < 0.0001), those in the intervention arm
increased lignan consumption by 67 6 3 lg/day (p < 0.0001;
in comparison to the control group: þ 3 6 2 lg/day; p ¼
0.002). The major dietary sources of lignans during the PPT
( 5% of total lignan intake) were whole grain rice or pasta
(15%), broccoli (9%), coffee (8%) and spaghetti with tomato
sauce (6%). The primary sources of lariciresinol, matairesinol,
pinoresinol and secoisolariciresinol were broccoli (26%),
whole grain rice or pasta (68%), tea (14%) and whole grain
rice or pasta (14%), respectively. Except for broccoli (11.6 vs.
12.5 g/day for those with any vs. no adenoma recurrence; p
¼ 0.01), intake of major sources of lignans did not vary by
adenoma recurrence status (data not shown). Total proantho-
cyanidin intake increased from 111 to 154 mg/day from base-
line during the ﬁrst 3 years of the trial (p < 0.0001), as the
intervention group increased their proanthocyanidin intake
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Int. J. Cancer: 130, 1649–1659 (2012) 2011 UICCby 81 6 3 mg/day (p < 0.0001; in comparison to the control
group: þ 0.7 6 2 mg/day; p ¼ 0.05). The primary dietary
sources of proanthocyanidins during the PPT ( 5% of total
intake) were apples (30.2%), other fruits (grapes, plums and
pineapples: 17.3%), chocolate (14.1%), tea (9.3%) and dry
beans (8.7%). Of the major dietary proanthocyanidin sources,
Table 1. Proportions and medians (interquartile ranges) of participant characteristics in the Polyp Prevention Trial by adenoma recurrence at
T4 (n ¼ 1,859)
1
Characteristics
Adenoma recurrence (T4)
None Any High risk Advanced
Median (IQR) or %
Median
(IQR) or % p Value
2
Median
(IQR) or % p Value
2
Median
(IQR) or % p Value
2
Sample size (%) 1,123 (60) 736 (40) 226 (12) 123 (7)
Baseline (T0)
Gender (% male) 60 72 <0.0001 76 <0.0001 72 0.01
Race (% Caucasian) 90 90 0.94 92 0.47 89 0.88
Education (%  high school) 24 25 0.62 28 0.24 27 0.51
Family history of colorectal
cancer (% yes)
3
27 27 0.92 31 0.29 27 1.00
Smoker (% current) 13 14 0.53 13 0.83 11 0.57
NSAID use (% yes)
4 35 32 0.13 29 0.09 24 0.02
Supplement use (% yes)
4 43 40 0.23 36 0.06 37 0.29
Hormone therapy (% yes)
4 14 8 <0.0001 7 0.003 7 0.02
Age (years) 61.0 (53.0–67.0) 64.0 (56.0–70.0) <0.0001 66.0 (60.0–71.0) <0.0001 67.0 (60.0–72.0) <0.0001
Body mass index (kg/m
2) 27.2 (24.5–30.1) 27.5 (25.1–30.4) 0.05 27.8 (25.2–30.9) 0.04 27.7 (25.1–31.2) 0.08
Physical activity (hr/week)
5 8.25 (3.90–15.0) 8.36 (3.84–15.9) 0.70 8.66 (3.50–15.8) 0.98 8.38 (3.65–18.7) 0.98
Trial (T1, T2 and T3)
6
Daily dietary intake
Alcohol (g) 0.96 (0.00–8.92) 1.55 (0.00–9.54) 0.30 0.99 (0.00–7.41) 0.73 0.99 (0.00–8.98) 0.87
Energy (1,000 kcals) 1.77 (1.52–2.08) 1.79 (1.54–2.09) 0.36 1.80 (1.57–2.05) 0.60 1.79 (1.57–2.02) 0.71
Total fat (g) 48.6 (36.7–64.8) 50.0 (38.2–65.8) 0.22 51.9 (41.3–65.6) 0.05 52.9 (41.6–64.7) 0.10
Saturated fat (g) 18.1 (13.1–24.8) 18.6 (13.8–25.4) 0.25 19.4 (14.4–25.5) 0.05 19.3 (14.4–25.5) 0.13
Lignans (lg) 165 (122–223) 170 (124–220) 0.97 161 (122–211) 0.49 171 (122–212) 0.68
Lariciresinol (lg) 48.4 (33.3–66.5) 48.8 (35.2–64.7) 0.91 48.4 (34.4–63.6) 0.70 49.8 (35.9–63.7) 0.93
Matairesinol (lg) 13.3 (7.05–27.4) 13.0 (6.92–27.1) 0.30 11.6 (6.61–26.6) 0.15 11.5 (6.61–26.6) 0.21
Pinoresinol (lg) 20.0 (13.2–29.2) 20.6 (13.4–29.5) 0.52 20.1 (13.4–28.9) 0.90 20.7 (13.4–28.9) 0.92
Secoisolariciresinol (lg) 77.2 (58.8–102) 77.7 (58.1–102) 0.81 75.2 (57.5–102) 0.31 77.9 (54.5–106) 0.65
Proanthocyanidins (mg) 152 (98.4–223) 154 (101–225) 0.88 151 (107–212) 0.81 150 (105–206) 0.56
Monomers (mg) 16.0 (10.3–26.0) 16.5 (10.7–25.4) 0.85 15.9 (10.6–24.2) 0.74 15.7 (10.5–23.5) 0.52
Dimers (mg) 22.3 (14.3–31.2) 22.7 (15.0–30.9) 0.85 22.4 (15.4–30.6) 0.85 22.3 (15.4–29.9) 0.67
Trimers (mg) 10.8 (7.22–16.0) 11.3 (6.91–16.0) 0.88 11.8 (7.07–15.4) 0.89 11.9 (7.12–15.0) 0.85
4–6 mers (mg) 30.5 (19.8–46.5) 31.4 (19.1–47.4) 0.77 31.8 (19.7–44.9) 0.98 30.9 (18.9–44.9) 0.69
7–10 mers (mg) 21.7 (13.3–34.0) 22.1 (13.1–34.1) 0.76 22.0 (13.6–32.0) 1.00 21.3 (13.5–31.6) 0.57
Polymers (mg) 44.1 (25.2–70.5) 43.8 (24.9–72.8) 0.96 42.7 (24.5–66.9) 0.53 42.2 (23.2–62.6) 0.41
1Participant characteristics stratiﬁed by adenoma recurrence have been previously presented.
42 All comparisons against the no adenoma recurrence
group. p Values for differences in proportions were calculated using Fisher’s exact test. p Values for differences in medians were calculated using
Wilcoxon rank-sum test.
3Family history of colorectal cancer was deﬁned as having  1 ﬁrst-degree relative with colorectal cancer at baseline.
4Regular non-steroidal anti-inﬂammatory drug (NSAID) use, hormone therapy and supplement use were tested at baseline and use throughout the
ﬁrst three trial years. Regular dietary supplement use was deﬁned as taking supplement  1 week. Regular medication use, including NSAIDs, was
deﬁned as taking medication  1 month. Hormone replacement therapy included both unopposed estrogen and estrogen/progestin combinations.
5Physical activity was deﬁned as self-reported time typically spent for any type of moderate or vigorous physical activity.
6T1, T2, T3: mean values
per day of the ﬁrst 3 years of the trial for dietary variables.
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Int. J. Cancer: 130, 1649–1659 (2012) 2011 UICCindividuals with high risk adenoma recurrence had lower tea
intake than those with no adenoma recurrence (5.93 vs. 12.9
g/day) and lower dry bean intake (11.3 vs. 15.4 g/day).
Our power calculation revealed that we had 99% and 96%
power to detect OR of 0.88, 0.79 and 0.70 in the second,
third and fourth quartiles (relative to the ﬁrst quartile) for
any recurrence and for an advanced recurrence, respectively.
Overall, consumption of total or individual lignans during
the ﬁrst 3 years of the trial was not associated with adenoma
recurrence (Table 2); adjusting for dietary ﬁber, which was
closely correlated with lignan consumption during the trial
(r ¼ 0.77), or saturated fat intake did not alter these associa-
tion (results not shown). Similarly, consumption of proantho-
cyanidins, overall or for polymers of varying length, was not
associated with adenoma recurrence (Table 3); adjusting
for saturated fat intake, which may affect microbial
Table 2. Association between daily lignan intake during the trial and colorectal adenoma recurrence in the Polyp Prevention Trial (n ¼ 1,859)
Lignans quartiles
1 (lg/day)
Adenoma recurrence (T4)
No Any High risk
n (%) n (%) OR (95% CI)
2 OR (95% CI)
3 n (%) OR (95% CI)
2 OR (95% CI)
3
Total Lignans
<123 286 (61.5) 179 (38.5) 1.00
4 1.00 57 (12.3) 1.00 1.00
123–167 287 (61.7) 178 (38.3) 0.98 (0.75–1.29) 0.99 (0.76–1.30) 61 (13.1) 1.06 (0.70–1.59) 1.07 (0.71–1.61)
168–222 266 (57.2) 199 (42.8) 1.25 (0.96–1.65) 1.26 (0.96–1.65) 58 (12.5) 1.19 (0.78–1.81) 1.21 (0.79–1.85)
>223 284 (61.2) 180 (38.8) 1.15 (0.86–1.53) 1.16 (0.87–1.56) 50 (10.8) 1.09 (0.69–1.72) 1.11 (0.70–1.75)
p trend
5 0.17 0.15 0.59 0.55
Lariciresinol
<34.0 296 (63.7) 169 (36.3) 1.00 1.00 54 (11.6) 1.00 1.00
34.0–48.4 268 (57.6) 197 (42.4) 1.32 (1.01–1.73) 1.32 (1.01–1.73) 57 (12.3) 1.20 (0.79–1.83) 1.21 (0.80–1.85)
48.5–66.0 272 (58.5) 193 (41.5) 1.28 (0.97–1.68) 1.29 (0.98–1.69) 67 (14.4) 1.41 (0.93–2.12) 1.40 (0.93–2.12)
>66.0 287 (61.9) 177 (38.1) 1.20 (0.90–1.60) 1.20 (0.90–1.59) 48 (10.3) 1.11 (0.71–1.74) 1.10 (0.70–1.73)
p trend 0.21 0.22 0.41 0.45
Matairesinol
<6.99 276 (59.4) 189 (40.6) 1.00 1.00 63 (13.5) 1.00 1.00
6.99–13.1 283 (60.9) 182 (39.1) 0.92 (0.70–1.20) 0.92 (0.70–1.20) 57 (12.3) 0.86 (0.57–1.29) 0.84 (0.55–1.26)
13.2–27.3 280 (60.2) 185 (39.8) 0.99 (0.75–1.29) 0.99 (0.76–1.30) 52 (11.2) 0.86 (0.57–1.31) 0.85 (0.56–1.30)
>27.3 284 (61.2) 180 (38.8) 1.03 (0.79–1.36) 1.04 (0.79–1.37) 54 (11.6) 1.04 (0.68–1.58) 1.05 (0.68–1.60)
p trend 0.68 0.66 0.86 0.80
Pinoresinol
<13.3 285 (61.3) 180 (38.7) 1.00 1.00 54 (11.6) 1.00 1.00
13.3–20.2 286 (61.5) 179 (38.5) 1.00 (0.76–1.31) 1.00 (0.76–1.32) 69 (12.9) 1.11 (0.73–1.68) 1.12 (0.74–1.70)
20.3–29.3 275 (59.1) 190 (40.9) 1.10 (0.84–1.45) 1.10 (0.84–1.44) 57 (12.3) 1.08 (0.71–1.66) 1.07 (0.70–1.64)
>29.3 277 (59.7) 187 (40.3) 1.10 (0.83–1.46) 1.10 (0.83–1.45) 55 (11.9) 1.04 (0.67–1.60) 1.02 (0.66–1.59)
p trend 0.40 0.42 0.88 0.94
Secoisolariciresinol
<58.7 276 (59.4) 189 (40.6) 1.00 1.00 62 (13.3) 1.00 1.00
58.7–77.4 288 (61.9) 177 (38.1) 1.00 (0.76–1.32) 0.87 (0.66–1.14) 58 (12.5) 0.84 (0.55–1.26) 0.85 (0.56–1.29)
77.5–102 276 (59.4) 189 (40.6) 1.10 (0.84–1.44) 1.02 (0.77–1.34) 50 (10.8) 0.86 (0.56–1.32) 0.87 (0.56–1.34)
>102 283 (61.0) 181 (39.0) 1.10 (0.83–1.45) 1.01 (0.75–1.35) 56 (12.1) 0.99 (0.63–1.55) 1.02 (0.65–1.61)
p trend 0.93 0.98 0.92 0.98
1Lignan intake in quartiles (Q1–Q4) by the mean consumption during the ﬁrst three trial years.
2Multivariate OR and 95% CI models were adjusted
for age quartiles (<55, 55–62, 63–69, >69 years), sex and average energy intake (continuous) during the ﬁrst three trial years.
3Multivariate OR
and 95% CI models were adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex, average BMI (<25, 25.0–29.9,  30 kg/m
2), regular
NSAID use at baseline and average energy intake (continuous) during the ﬁrst three trial years.
4Reference category.
5The ln-transformed median
intakes in lg/day of each quartile were used as a continuous score variable to determine the p value for trend.
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Int. J. Cancer: 130, 1649–1659 (2012) 2011 UICCTable 3. Association between daily proanthocyanidin intake during the trial and colorectal adenoma recurrence in the Polyp Prevention Trial
(n ¼ 1,859)
Adenoma recurrence (T4)
No Any High risk
Proanthocyanidin
quartiles
1 (mg/day) n (%) n (%) OR (95% CI)
2 OR (95% CI)
3 n (%) OR (95% CI)
2 OR (95% CI)
3
Total proanthocyanidin
<99.1 286 (61.5) 179 (38.5) 1.00
4 1.00 49 (10.5) 1.00 1.00
99.2–153 280 (60.2) 185 (39.8) 1.09 (0.83–1.43) 1.13 (0.85–1.48) 66 (14.2) 1.39 (0.91–2.11) 1.53 (0.99–2.35)
154–223 279 (60.0) 186 (40.0) 1.13 (0.86–1.48) 1.20 (0.90–1.60) 60 (12.9) 1.29 (0.84–1.98) 1.52 (0.96–2.40)
>223 278 (59.9) 186 (40.1) 1.14 (0.86–1.52) 1.27 (0.91–1.76) 51 (11.0) 1.15 (0.73–1.82) 1.50 (0.89–2.53)
P trend
5 0.33 0.14 0.55 0.11
Monomer
<10.5 292 (62.8) 173 (37.2) 1.00 1.00 54 (11.6) 1.00 1.00
10.5–16.2 278 (59.8) 187 (40.2) 1.16 (0.89–1.53) 1.18 (0.89–1.35) 62 (13.3) 1.23 (0.81–1.86) 1.26 (0.82–1.92)
16.3–25.7 268 (57.6) 197 (42.4) 1.29 (0.98–1.70) 1.29 (0.98–1.71) 60 (12.9) 1.29 (0.84–1.97) 1.31 (0.85–2.03)
>25.7 285 (61.4) 179 (38.6) 1.13 (0.86–1.50) 1.14 (0.86–1.52) 50 (10.8) 1.02 (0.65–1.60) 1.04 (0.66–1.64)
p trend 0.31 0.32 0.87 0.83
Dimer
<14.6 293 (63.0) 172 (37.0) 1.00 1.00 52 (11.2) 1.00 1.00
14.6–22.4 273 (58.7) 192 (41.3) 1.25 (0.95–1.63) 1.28 (0.98–1.69) 62 (13.3) 1.37 (0.90–2.09) 1.39 (0.91–2.12)
22.5–31.0 274 (58.9) 191 (41.1) 1.24 (0.94–1.63) 1.29 (0.97–1.73) 58 (12.5) 1.38 (0.88–2.15) 1.36 (0.87–2.14)
>31.0 283 (61.0) 181 (39.0) 1.17 (0.88–1.56) 1.25 (0.92–1.70) 54 (11.6) 1.38 (0.85–2.22) 1.39 (0.86–2.25)
p trend 0.25 0.14 0.51 0.17
Trimer
<7.12 270 (58.1) 195 (41.9) 1.00 1.00 57 (12.3) 1.00 1.00
7.12–10.9 302 (64.9) 163 (35.1) 0.74 (0.56–0.97( 0.76 (0.58–1.00) 48 (10.3) 0.74 (0.48–1.14) 0.81 (0.52–1.25)
11.0–16.0 271 (58.3) 194 (41.7) 1.03 (0.79–1.35) 1.07 (0.81–1.43) 69 (14.8) 1.28 (0.85–1.93) 1.53 (0.99–2.37)
>16.0 280 (60.3) 184 (39.7) 0.94 (0.70–1.24) 0.98 (0.72–1.34) 52 (11.2) 0.91 (0.58–1.43) 1.12 (0.69–1.83)
p trend 0.91 0.73 0.72 0.25
4–6mers
<19.4 274 (58.8) 192 (41.2) 1.00 1.00 55 (11.8) 1.00 1.00
19.4–30.9 298 (64.2) 166 (35.8) 0.80 (0.61–1.05) 0.83 (0.63–1.10) 54 (11.6) 0.93 (0.61–1.41) 1.01 (0.66–1.56)
31.0–46.9 276 (59.4) 189 (40.6) 1.03 (0.78–1.34) 1.09 (0.82–1.45) 67 (14.4) 1.27 (0.84–1.92) 1.50 (0.97–2.33)
>46.9 275 (59.3) 189 (40.7) 1.02 (0.77–1.36) 1.12 (0.18–1.55) 50 (10.8) 0.94 (0.60–1.92) 1.20 (0.72–2.00)
p trend 0.59 0.34 0.78 0.22
7–10mers
<13.2 280 (60.2) 185 (39.8) 1.00 1.00 51 (11.0) 1.00 1.00
13.2–21.8 288 (62.9) 177 (38.1) 0.93 (0.71–1.22) 0.96 (0.73–1.27) 61 (13.1) 1.16 (0.76–1.77) 1.27 (0.83–1.96)
21.9–34.0 276 (59.4) 189 (40.6) 1.09 (0.83–1.42) 1.15 (0.86–1.54) 65 (14.0) 1.34 (0.88–2.03) 1.57 (1.00–2.47)
>34.0 279 (60.1) 185 (39.9) 1.04 (0.79–1.38) 1.14 (0.82–1.58) 49 (10.6) 0.99 (0.63–1.56) 1.27 (0.75–2.15)
p trend 0.57 0.32 0.75 0.19
Polymers (>10)
<25.1 278 (59.8) 187 (40.2) 1.00 1.00 60 (12.9) 1.00 1.00
25.1–43.9 281 (60.4) 184 (39.6) 0.97 (0.74–1.26) 0.99 (0.75–1.31) 59 (12.7) 0.92 (0.61–1.39) 1.00 (0.66–1.53)
44.0–71.6 290 (62.4) 175 (37.6) 0.94 (0.72–1.23) 1.00 (0.74–1.34) 53 (11.4) 0.86 (0.57–1.31) 1.00 (0.63–1.57)
>71.6 274 (59.1) 190 (40.9) 1.07 (0.81–1.41) 1.17 (0.84–1.65) 54 (11.6) 0.93 (0.61–1.43) 1.19 (0.70–2.03)
p trend 0.76 0.46 0.64 0.62
1Proanthocyanidin intake in quartiles (Q1–Q4) by the mean consumption during the ﬁrst three trial years.
2Multivariate OR and 95% CI models were
adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex and average energy intake (continuous) during the ﬁrst three trial years.
3Multivariate OR and 95% CI models were adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex, average BMI (<25, 25.0–29.9,  30 kg/
m
2), regular NSAID use at baseline and average energy (continuous) and saturated fat intake (<13.4, 13.4–18.3, 18.4–25.0, >25.0 g/day) during
the ﬁrst three trial years.
4Reference category.
5The ln-transformed median intakes in mg/day of each quartile were used as a continuous score
variable to determine the p value for trend.proanthocyanidin metabolism in the small intestine, but not
dietary ﬁbre, which was also correlated with lignan consump-
tion during the trial (r ¼ 0.71) did alter these associations.
After stratiﬁcation by gender, total lignan intake during
the ﬁrst three trial years was positively associated with any
adenoma recurrence in women (highest vs. lowest lignan
intake quartile OR ¼ 2.07, 95% CI: 1.22–3.52, p trend ¼
0.004), but not in men (OR ¼ 0.91, 95% CI ¼ 0.64–1.30; p
interaction ¼ 0.04; Table 4). Total T0 lignan intake, change
in lignan intake from baseline, and ﬁbre consumption were
not associated with any adenoma recurrence in women or
men (results not shown). Total proanthocyanidin intake was
positively associated with high risk adenoma recurrence in
men (OR ¼ 2.00, 95% CI ¼ 1.08–3.70, p trend ¼ 0.02), but
no signiﬁcant interaction was noted between gender and
proanthocyanidin intake (p interaction ¼ 0.34; Table 4).
Stratiﬁcation by age, BMI or regular NSAID use did not
reveal any other associations between consumption of lignans
Table 4. Association between daily lignan and proanthocyanidin consumption and colorectal adenoma recurrence in the Polyp Prevention
Trial stratiﬁed by gender (n ¼ 1,859)
Intake quartiles
1
Adenoma Recurrence (T4)
No Any High Risk
n (%) n (%) OR (95% CI)
2 OR (95% CI)
3 n (%) OR (95% CI)
2 OR (95% CI)
3
Lignan (lg/day)
Women
<123 131 (72.8) 49 (27.2) 1.00
4 1.00 15 (8.3) 1.00 1.00
123–167 117 (70.5) 49 (29.5) 1.20 (0.74–1.94) 1.24 (0.76–2.01) 19 (11.4) 1.53 (0.71–3.28) 1.54 (0.72–3.31)
168–222 100 (65.8) 52 (34.2) 1.68 (1.02–2.77) 1.73 (1.04–2.86) 8 (5.3) 0.87 (0.33–2.27) 0.87 (0.33–2.28)
>223 103 (65.6) 54 (34.4) 1.98 (1.17–3.35) 2.07 (1.22–3.52) 12 (7.6) 1.64 (0.64–4.17) 1.61 (0.63–4.14)
p trend
5 0.006 0.004 0.49 0.51
Men
<123 155 (54.4) 130 (45.6) 1.00 1.00 42 (14.7) 1.00 1.00
123–167 170 (56.9) 129 (43.1) 0.90 (0.65–1.26) 0.90 (0.65–1.26) 42 (14.0) 0.91 (0.56–1.48) 0.91 (0.56–1.50)
168–222 166 (53.0) 147 (47.0) 1.11 (0.80–1.54) 1.10 (0.79–1.52) 50 (16.0) 1.25 (0.77–2.01) 1.27 (0.78–2.06)
>223 181 (59.0) 126 (41.0) 0.91 (0.64–1.29) 0.91 (0.64–1.30) 38 (12.4) 0.96 (0.57–1.63) 0.99 (0.58–1.68)
p trend 0.87 0.87 0.81 0.74
p interaction
5 0.05 0.04 0.83 0.83
Proanthocyanidin (mg/day)
Women
<99.1 106 (68.8) 48 (31.2) 1.00 1.00 16 (10.4) 1.00 1.00
99.2–153 130 (69.9) 56 (30.1) 0.95 (0.59–1.53) 0.90 (0.55–1.47) 16 (8.6) 0.73 (0.33–1.59) 0.70 (0.31–1.56)
154–223 119 (70.4) 50 (29.6) 1.03 (0.63–1.70) 0.96 (0.56–1.63) 11 (6.5) 0.64 (0.27–1.53) 0.61 (0.24–1.53)
>223 96 (65.8) 50 (34.2) 1.28 (0.75–2.20) 1.11 (0.61–2.10) 11 (7.5) 0.78 (0.31–1.99) 0.73 (0.26–2.10)
p trend 0.37 0.77 0.49 0.45
Men
<99.1 180 (57.9) 131 (42.1) 1.00 1.00 33 (10.6) 1.00 1.00
99.2–153 150 (53.8) 129 (46.2) 1.18 (0.84–1.63) 1.26 (0.90–1.76) 50 (17.9) 1.79 (1.09–2.96) 2.11 (1.26–3.54)
154–223 160 (54.1) 136 (45.9) 1.19 (0.86–1.64) 1.36 (0.96–1.93) 49 (16.6) 1.67 (1.01–2.75) 2.12 (1.24–3.61)
>223 182 (57.2) 136 (42.8) 1.09 (0.78–1.53) 1.35 (0.91–2.00) 40 (12.6) 1.33 (0.78–2.75) 2.00 (1.08–3.70)
p trend 0.54 0.10 0.28 0.02
p interaction 0.72 0.65 0.34 0.34
1Lignan and proanthocyanidin intake in quartiles (Q1–Q4) by the mean consumption during the ﬁrst three trial years.
2Multivariate OR and 95% CI
models were adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex and average energy intake (continuous) during the ﬁrst three trial
years.
3Multivariate OR and 95% CI models were adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex, average BMI (<25, 25.0–29.9,
 30 kg/m
2) and regular NSAID use at baseline, and average energy (continuous) and saturated fat intake (<13.4, 13.4–18.3, 18.4–25.0, >25.0 g/
day; only for proanthocyanidins) during the ﬁrst three trial years.
4Reference category.
5The ln-transformed median intakes of each quartile were
used as a continuous score variable to determine the p value for trend. The ln-transformed median intakes of each quartile were used as a
continuous score variable and sex as categorical variable to determine the p value for the interaction.
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shown).
For those individuals consuming the median or below me-
dian intake of saturated fat during the trial, lignan intake was
positively associated with any (OR ¼ 1.94, 95% CI ¼ 1.17–
3.19, p trend ¼ 0.009) and high risk adenoma recurrence
(OR ¼ 3.21, 95% CI ¼ 1.36–7.59, p trend ¼ 0.008; Table 5);
the interaction between saturated fat and lignan intake was
statistically signiﬁcant for high risk adenoma recurrence (p ¼
0.01) but not for any adenoma recurrence (p ¼ 0.32). The
effect modiﬁcation was not statistically signiﬁcant for ﬁbre
(data not shown). Total proanthocyanidin intake was posi-
tively associated with any adenoma recurrence in individuals
with a saturated fat intake equal to or below the median (OR
¼ 1.53, 95% CI ¼ 0.95–2.46, p trend ¼ 0.05; Table 5).
Discussion
The objective of this study was to prospectively examine the
association between consumption of lignans and proantho-
cyanidins and colorectal adenoma recurrence. Overall, dietary
Table 5. Association between daily lignan and proanthocyanidin consumption and colorectal adenoma recurrence in the Polyp Prevention
Trial stratiﬁed by daily saturated fat intake (n ¼ 1,859)
Intake quartiles
1
Adenoma Recurrence (T4)
No Any High Risk
n (%) n (%) OR (95% CI)
2 OR (95% CI)
3 n (%) OR (95% CI)
2 OR (95% CI)
3
Lignans (lg/day)
Saturated fat   18.3 g/day
<123 106 (66.3) 54 (33.7) 1.00
4 1.00 12 (7.5) 1.00 1.00
123–167 120 (61.2) 76 (38.8) 1.36 (0.86–2.13) 1.37 (0.87–2.16) 21 (10.7) 1.67 (0.76–3.67) 1.77 (0.80–3.92)
168–222 154 (59.7) 104 (40.3) 1.62 (1.03–2.54) 1.63 (1.04–2.58) 28 (10.9) 2.00 (0.90–4.42) 2.12 (0.95–4.72)
>223 190 (60.1) 126 (39.9) 1.80 (1.10–2.95) 1.94 (1.17–3.19) 39 (12.3) 3.03 (1.29–7.11) 3.21 (1.36–7.59)
p trend
5 0.01 0.009 0.01 0.008
Saturated fat >18.3 g/day
<123 180 (59.0) 125 (41.0) 1.00 1.00 45 (14.8) 1.00 1.00
123–167 167 (62.1) 102 (37.9) 0.82 (0.58–1.16) 0.85 (0.60–1.20) 40 (14.9) 0.97 (0.59–1.59) 0.96 (0.58–1.58)
168–222 112 (54.1) 95 (45.9) 1.19 (0.82–1.74) 1.26 (0.86–1.85) 30 (14.5) 1.29 (0.74–2.27) 1.28 (0.73–2.25)
>223 94 (63.5) 54 (36.5) 0.78 (0.49–1.25) 0.89 (0.56–1.43) 11 (7.4) 0.61 (0.28–1.34) 0.61 (0.28–1.34)
p trend 0.85 0.86 0.62 0.61
p interaction
5 0.35 0.32 0.02 0.01
Proanthocyanidins (mg/day)
Saturated fat   18.3 g/day
<99.1 109 (65.3) 58 (34.7) 1.00 1.00 12 (7.2) 1.00 1.00
99.2–153 122 (62.2) 74 (37.8) 1.20 (0.77–1.87) 1.21 (0.77–1.88) 23 (11.7) 1.73 (0.80–3.75) 1.70 (0.78–3.70)
154–223 154 (58.6) 109 (41.4) 1.52 (0.99–2.34) 1.54 (1.00–2.37) 30 (11.4) 1.90 (0.89–4.07) 1.93 (0.90–4.15)
>223 185 (60.9) 119 (39.1) 1.53 (0.95–2.45) 1.53 (0.95–2.46) 35 (11.5) 2.06 (0.90–4.70) 2.01 (0.87–4.64)
p trend 0.05 0.05 0.10 0.11
Saturated Fat >18.3 g/day
<99.1 177 (59.4) 121 (40.6) 1.00 1.00 37 (12.4) 1.00 1.00
99.2–153 158 (58.7) 111 (41.3) 1.08 (0.76–1.54) 1.08 (0.76–1.54) 43 (16.0) 1.40 (0.84–2.34) 1.44 (0.86–2.42)
154–223 125 (61.9) 77 (38.1) 0.97 (0.66–1.43) 0.94 (0.64–1.40) 30 (14.9) 1.28 (0.72–2.25) 1.26 (0.71–2.24)
>223 93 (58.1) 67 (41.9) 1.08 (0.70–1.68) 1.10 (0.71–1.71) 16 (10.0) 0.95 (0.47–1.90) 0.99 (0.49–2.00)
p trend 0.85 0.85 0.82 0.77
p interaction 0.42 0.39 0.13 0.13
1Lignan and proanthocyanidin intake in quartiles (Q1–Q4) by the mean consumption during the ﬁrst three trial years. Saturated fat intake below or
above the median of the mean intake during the ﬁrst three trial years.
2Multivariate OR and 95% CI models were adjusted for age quartiles (<55,
55–62, 63–69, >69 years), sex and average energy intake (continuous) during the ﬁrst three trial years.
3Multivariate OR and 95% CI models were
adjusted for age quartiles (<55, 55–62, 63–69, >69 years), sex, average BMI (<25, 25.0–29.9,  30 kg/m
2) and regular NSAID use at baseline,
and average energy intake (continuous) during the ﬁrst three trial years.
4Reference category.
5The ln-transformed median intakes of each quartile
were used as a continuous score variable to determine the p value for trend. The ln-transformed median intakes of each quartile were used as a
continuous score variable and saturated fat intake as categorical variable (  or > median intake) to determine the p value for the interaction.
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Int. J. Cancer: 130, 1649–1659 (2012) 2011 UICClignan and proanthocyanidin intake was not associated with
colorectal adenoma recurrence. However, when stratiﬁed by
gender, high lignan intake was associated with an increased
risk of any adenoma recurrence in women. Furthermore,
high lignan intake was associated with an increased risk of
any and high risk adenoma recurrence in individuals that
consumed saturated fat at or below the median intake level.
Our results suggest that high lignan intake may increase the
risk of adenoma recurrence in women and individuals with
low saturated fat intake.
The association between lignans and their metabolites
enterolactone and enterodiol in plasma and colorectal neopla-
sia has been mixed in human studies. In a Canadian case-
control study, lignan consumption was inversely associated
with colorectal cancer.
39 Similarly, in a Dutch endoscopy-
based case-control study, plasma enterodiol, but not entero-
lactone, concentrations were inversely associated with inci-
dent colorectal adenoma risk.
40 However, the authors could
not reproduce the inverse relationship between enterodiol
and colorectal cancer risk in a subsequent nested case-control
study.
41 Moreover, they reported, similar to our ﬁndings, a
gender speciﬁc increased risk of colorectal cancer with high
enterolactone concentrations in women.
41 In contrast, both
Danish and English nested case-control studies reported that
high plasma enterolactone concentrations decreased the risk
of colorectal cancer in women
18,19; however, similar to our
results, lignan consumption tended to be associated with
increased colorectal cancer risk in the English study.
18
Dietary lignan sources partly explain the mixed results
across different studies; for example, 88% of dietary lignans
were from ﬂaxseed in the Canadian study,
11 a food item that
was rarely consumed in the 1990s in the U.S. Flaxseed is not
only a good dietary source of lignans but also of omega-3
fatty acids, which may protect against colorectal tumorigene-
sis. In addition, diet composition, speciﬁcally dietary ﬁber
and lipids, may impact the metabolism of plant lignans to
the more bioactive enterolactone and enterodiol and, there-
fore the association between dietary lignans and colorectal
carcinogenesis.
18,20 For example, lipid consumption (in par-
ticular the consumption of saturated fats) decreases the con-
version of dietary plant lignans to enterolignans
6,20; thus,
enterolignan concentrations may be higher in individuals
with a low saturated fat intake, which may partly explain
why the detrimental effect of high lignan consumption on
adenoma recurrence can only be observed in the low satu-
rated fat intake group. Alternatively, the lignan to lipid ratio
may inﬂuence cancer risk because lignans and lipids both al-
ter the metabolism of steroid hormones,
6,21 which are
involved in the etiology of colorectal tumorigenesis. Dietary
lipids may modify the effect of dietary ﬁbre, which is closely
associated with lignan consumption,
6,20 on colorectal carcino-
genesis, as has been demonstrated in animal models.
42–44 The
gender difference in risk of colorectal neoplasms observed in
this and other studies,
18,19,41 may be related to the ability of
lignans to bind to estrogen receptors and thereby antagoniz-
ing endogenously synthesized estrogen
6,18,21 but there is some
evidence to suggest that this may also increase proliferation
of colonic epithelial cells.
2,45
The number of human studies that have investigated the
association between proanthocyanidin consumption and risk
of colorectal neoplasms is limited. A Scottish and an Italian
case-control study reported an inverse association between
proanthocyanidin intake and colorectal cancer risk.
29,30 In
contrast, a second Scottish case-control study, as well as the
prospective Iowa Women’s Health Study detected no associa-
tion with colorectal cancer,
31,32 which is similar to our
results. Variation in dietary proanthocyanidin sources (apples
and tea in most studies), may partly explain differences in
associations. We previously reported that increasing dry bean
intake reduced the risk of advanced adenoma recurrence in
the PPT.
46 Although proanthocyanidins have been considered
for prevention and therapy of cancer,
28 high proanthocyani-
din intake has risks and potentially pro-carcinogenic effects.
Proanthocyanidins can inhibit the growth of the intestinal
microbial ﬂora, chelate minerals and thereby decrease their
absorption, inhibit intestinal enzymes, and are toxic at high
concentrations.
2,45 Other dietary components may also inﬂu-
ence the association between proanthocyanidins, especially
for polymeric proanthocyanidins, and cancer risk, as only
monomeric, dimeric or trimeric proanthocyanidins are
absorbed.
27 This is, to our knowledge, the ﬁrst study to
examine the association between consumption of proantho-
cyanidins and risk of colorectal adenomas. The association
between consumption of proanthoycyanidins and risk of
colorectal cancer may vary from the association with colo-
rectal adenomas.
Strengths of our study include the prospective, annual col-
lection of dietary data and the use of a questionnaire that
was speciﬁcally designed to accurately estimate consumption
of ﬁbre, fruit and vegetables.
34,35 The immediate review of all
questionnaires by registered dieticians further improved the
accuracy of dietary data,
36 and validated proanthocyanidin
and lignan databases were used to estimate proanthocyanidin
and lignan intake.
8,10,26,37,38 Another major strength was the
complete outcome surveillance, which included colonoscopies
at baseline and at the end of T1 and T4 and independent,
histological characterization of all colorectal lesions by two
pathologists, which minimized outcome misclassiﬁcation.
Limitations of this study include that the FFQ did not
speciﬁcally ask about intake of sesame and ﬂax seed, which
are enriched in lignans and have shown a protective effect in
Canadian studies.
8,11,39 The use of sesame and ﬂax seed in
the U.S. was low in the 1990s; thus, we cannot exclude the
possibility that at higher intake levels, the associations might
be different. In addition, the FFQ was not speciﬁcally devel-
oped and validated for estimating proanthocyanidin and
lignan intake and several databases were used to estimate
lignan intake; however, 58 of 65 food and beverage items
were estimated from a single lignan database. These results
from the PPT population, which had a history of adenomas,
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healthy lifestyle, and had a comparably low lignan intake
(167 lg/day) compared to the European and Canadian stud-
ies (200–1000 lg/day),
18,20,39 may be limited in their general-
izability. Use of dietary supplements rich in proanthocyani-
dins and lignans was low in the PPT and, thus, not included
in the intake estimation, which may cause random and sys-
tematic misclassiﬁcation of proanthocyanidin and lignan con-
sumption.
47 Other potential sources of random and system-
atic misclassiﬁcation relate to dietary assessment technique,
proanthocyanidin and lignan databases, variations in food
quantities of recipes or grouped foods, variability in lignan
and proanthocyanidin content due to climatic, growing, soil
and harvesting conditions of plants and storage and prepara-
tion conditions of foods. Furthermore, participants were
aware of the expected dietary patterns and in 12% of partici-
pants T3 dietary data were obtained before an unscheduled
colonoscopy used for assessing adenoma recurrence.
There might be concerns regarding the size of the popula-
tion; however, a Monte-Carlo study indicated that we would
have 99% and 96% power to detect small to moderate sized
main effects for any recurrence and for an advanced recur-
rence, respectively. Observed differences might have arisen by
chance because this is a secondary analysis, which included
stratiﬁcation into subgroups, and participants were not spe-
ciﬁcally assigned to a lignan or proanthocyanidin rich diet.
However, the monotonic increase in ORs for adenoma recur-
rence with lignan intake in women and individuals that con-
sumed saturated fat below or equal to 18.3 g/day in combina-
tion with the biological plausibility for such an association is
unlikely due to chance and supports the assertion that, de-
spite potential dietary measurement error, the study had suf-
ﬁcient statistical power and participants were ranked robustly
enough to observe an association.
Conclusion
In conclusion, consumption of lignans or proanthocyanidins
was not associated with colorectal adenoma recurrence over-
all. However, high lignan intake may increase the risk of any
adenoma recurrence in women and in individuals with satu-
rated fat intake below or equal to 18.3 g/day, which suggests
gender and dietary fat may modify this association. Further
studies are needed to examine the importance and biological
role of lignans and proanthocyanidins in colorectal
carcinogenesis.
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